Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles

Jianliang Shen, Haoran Liu, Chaofeng Mu, Joy Wolfram, Wei Zhang, Han Cheon Kim, Guixian Zhu, Zhongbo Hu, Liang Nian Ji, Xuewu Liu, Mauro Ferrari, Zong Wan Mao, Haifa Shen

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Drug to carrier ratio is an important consideration in designing drug platforms, since a low loading capacity necessitates the use of high doses of carriers, which can result in side effects. Here, we have engineered a platform to co-deliver small molecule drugs and small interfering RNA (siRNA). This platform consists of cyclodextrin-grafted polyethylenimine (CP) functionalized mesoporous silica nanoparticles (MSNP). A unique multi-step encapsulation procedure was used to obtain a high loading capacity for doxorubicin (DOX) and siRNA oligos specific for the PKM2 gene that encodes pyruvate kinase M2, an enzyme catalyzing the final rate-limiting step in glycolysis. We systematically characterized this platform (CP-MSNP@DOX/PKM2) in vitro and evaluated its therapeutic efficacy in vivo with a mouse model of triple negative breast cancer (TNBC). Exposure of TNBC cells to CP-MSNP@DOX/PKM2 resulted in suppressed target gene expression, reduced cell proliferation, and enhanced apoptosis. Intravenous administration of the drug substantially decreased the tumor burden in comparison to DOX or siRNA monotherapy. In conclusion, we have developed a platform for efficient co-delivery of small molecule drugs and therapeutic siRNA.

Original languageEnglish (US)
Pages (from-to)5329-5341
Number of pages13
JournalNanoscale
Volume9
Issue number16
DOIs
StatePublished - Apr 28 2017
Externally publishedYes

Fingerprint

Chemotherapy
RNA
Encapsulation
Silicon Dioxide
Cyclodextrins
Polyethyleneimine
Genes
Doxorubicin
Silica
Small Interfering RNA
Nanoparticles
Pharmaceutical Preparations
Molecules
Cell proliferation
Cell death
Gene expression
Pyruvate Kinase
Tumors
Enzymes
Apoptosis

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles. / Shen, Jianliang; Liu, Haoran; Mu, Chaofeng; Wolfram, Joy; Zhang, Wei; Kim, Han Cheon; Zhu, Guixian; Hu, Zhongbo; Ji, Liang Nian; Liu, Xuewu; Ferrari, Mauro; Mao, Zong Wan; Shen, Haifa.

In: Nanoscale, Vol. 9, No. 16, 28.04.2017, p. 5329-5341.

Research output: Contribution to journalArticle

Shen, J, Liu, H, Mu, C, Wolfram, J, Zhang, W, Kim, HC, Zhu, G, Hu, Z, Ji, LN, Liu, X, Ferrari, M, Mao, ZW & Shen, H 2017, 'Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles', Nanoscale, vol. 9, no. 16, pp. 5329-5341. https://doi.org/10.1039/c7nr00377c
Shen, Jianliang ; Liu, Haoran ; Mu, Chaofeng ; Wolfram, Joy ; Zhang, Wei ; Kim, Han Cheon ; Zhu, Guixian ; Hu, Zhongbo ; Ji, Liang Nian ; Liu, Xuewu ; Ferrari, Mauro ; Mao, Zong Wan ; Shen, Haifa. / Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles. In: Nanoscale. 2017 ; Vol. 9, No. 16. pp. 5329-5341.
@article{3fb3ae346e6d4d498e7f9648c0ba975b,
title = "Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles",
abstract = "Drug to carrier ratio is an important consideration in designing drug platforms, since a low loading capacity necessitates the use of high doses of carriers, which can result in side effects. Here, we have engineered a platform to co-deliver small molecule drugs and small interfering RNA (siRNA). This platform consists of cyclodextrin-grafted polyethylenimine (CP) functionalized mesoporous silica nanoparticles (MSNP). A unique multi-step encapsulation procedure was used to obtain a high loading capacity for doxorubicin (DOX) and siRNA oligos specific for the PKM2 gene that encodes pyruvate kinase M2, an enzyme catalyzing the final rate-limiting step in glycolysis. We systematically characterized this platform (CP-MSNP@DOX/PKM2) in vitro and evaluated its therapeutic efficacy in vivo with a mouse model of triple negative breast cancer (TNBC). Exposure of TNBC cells to CP-MSNP@DOX/PKM2 resulted in suppressed target gene expression, reduced cell proliferation, and enhanced apoptosis. Intravenous administration of the drug substantially decreased the tumor burden in comparison to DOX or siRNA monotherapy. In conclusion, we have developed a platform for efficient co-delivery of small molecule drugs and therapeutic siRNA.",
author = "Jianliang Shen and Haoran Liu and Chaofeng Mu and Joy Wolfram and Wei Zhang and Kim, {Han Cheon} and Guixian Zhu and Zhongbo Hu and Ji, {Liang Nian} and Xuewu Liu and Mauro Ferrari and Mao, {Zong Wan} and Haifa Shen",
year = "2017",
month = "4",
day = "28",
doi = "10.1039/c7nr00377c",
language = "English (US)",
volume = "9",
pages = "5329--5341",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "16",

}

TY - JOUR

T1 - Multi-step encapsulation of chemotherapy and gene silencing agents in functionalized mesoporous silica nanoparticles

AU - Shen, Jianliang

AU - Liu, Haoran

AU - Mu, Chaofeng

AU - Wolfram, Joy

AU - Zhang, Wei

AU - Kim, Han Cheon

AU - Zhu, Guixian

AU - Hu, Zhongbo

AU - Ji, Liang Nian

AU - Liu, Xuewu

AU - Ferrari, Mauro

AU - Mao, Zong Wan

AU - Shen, Haifa

PY - 2017/4/28

Y1 - 2017/4/28

N2 - Drug to carrier ratio is an important consideration in designing drug platforms, since a low loading capacity necessitates the use of high doses of carriers, which can result in side effects. Here, we have engineered a platform to co-deliver small molecule drugs and small interfering RNA (siRNA). This platform consists of cyclodextrin-grafted polyethylenimine (CP) functionalized mesoporous silica nanoparticles (MSNP). A unique multi-step encapsulation procedure was used to obtain a high loading capacity for doxorubicin (DOX) and siRNA oligos specific for the PKM2 gene that encodes pyruvate kinase M2, an enzyme catalyzing the final rate-limiting step in glycolysis. We systematically characterized this platform (CP-MSNP@DOX/PKM2) in vitro and evaluated its therapeutic efficacy in vivo with a mouse model of triple negative breast cancer (TNBC). Exposure of TNBC cells to CP-MSNP@DOX/PKM2 resulted in suppressed target gene expression, reduced cell proliferation, and enhanced apoptosis. Intravenous administration of the drug substantially decreased the tumor burden in comparison to DOX or siRNA monotherapy. In conclusion, we have developed a platform for efficient co-delivery of small molecule drugs and therapeutic siRNA.

AB - Drug to carrier ratio is an important consideration in designing drug platforms, since a low loading capacity necessitates the use of high doses of carriers, which can result in side effects. Here, we have engineered a platform to co-deliver small molecule drugs and small interfering RNA (siRNA). This platform consists of cyclodextrin-grafted polyethylenimine (CP) functionalized mesoporous silica nanoparticles (MSNP). A unique multi-step encapsulation procedure was used to obtain a high loading capacity for doxorubicin (DOX) and siRNA oligos specific for the PKM2 gene that encodes pyruvate kinase M2, an enzyme catalyzing the final rate-limiting step in glycolysis. We systematically characterized this platform (CP-MSNP@DOX/PKM2) in vitro and evaluated its therapeutic efficacy in vivo with a mouse model of triple negative breast cancer (TNBC). Exposure of TNBC cells to CP-MSNP@DOX/PKM2 resulted in suppressed target gene expression, reduced cell proliferation, and enhanced apoptosis. Intravenous administration of the drug substantially decreased the tumor burden in comparison to DOX or siRNA monotherapy. In conclusion, we have developed a platform for efficient co-delivery of small molecule drugs and therapeutic siRNA.

UR - http://www.scopus.com/inward/record.url?scp=85018749536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018749536&partnerID=8YFLogxK

U2 - 10.1039/c7nr00377c

DO - 10.1039/c7nr00377c

M3 - Article

VL - 9

SP - 5329

EP - 5341

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 16

ER -